A diabetes drug created by Sanofi-Aventis has been granted regulatory approval for release in Europe. The drug will be approved for both children and adolescents to use.
Apidra, the new diabetes drug, will be used for children aged six years and over. The medicine will be generally used in combination with a basal insulin dose. Sanofi are understood to be excited by the decision.
The senior medical director of the diabetes-metabolism franchise, Riccardo Perfetti, reportedly commented: “Sanofi-aventis recognises the many challenges faced by children with diabetes and their families, and is committed to providing paediatric patients and their healthcare providers with new treatment options.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…